[Ways of correcting immunodeficiency at different stages of burns with the aim of prevention and treatment of sepsis].
Nazarov
I P
IP
Popov
A A
AA
Protopopov
B V
BV
Kokoulina
Zh N
ZhN
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000917:Antibody Formation; D000975:Antioxidants / Q000627:therapeutic use; D002056:Burns / Q000150:complications / Q000276:immunology* / Q000628:therapy*; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007111:Immunity, Cellular; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D018805:Sepsis / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D016060:Sorption Detoxification; D013949:Thymus Extracts / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000975:Antioxidants; D007376:Interleukin-2; D010455:Peptides; D013949:Thymus Extracts; D016308:Enkephalin, Leucine-2-Alanine; C036191:T-activin; C040996:enkephalin-Leu, Ala(2)-Arg(6)-